Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor.
Cimmino F, Avitabile M, Diskin SJ, Vaksman Z, Pignataro P, Formicola D, Cardinale A, Testori A, Koster J, de Torres C, Devoto M, Maris JM, Iolascon A, Capasso M. Cimmino F, et al. Among authors: testori a. Int J Cancer. 2018 Dec 1;143(11):2828-2837. doi: 10.1002/ijc.31822. Epub 2018 Oct 4. Int J Cancer. 2018. PMID: 30132831 Free PMC article.
Functional annotation and investigation of the 10q24.33 melanoma risk locus identifies a common variant that influences transcriptional regulation of OBFC1.
Cardinale A, Cantalupo S, Lasorsa VA, Montella A, Cimmino F, Succoio M, Vermeulen M, Baltissen MP, Esposito M, Avitabile M, Formicola D, Testori A, Bonfiglio F, Ghiorzo P, Scalvenzi M, Ayala F, Zambrano N, Iles MM, Xu M, Law MH, Brown KM, Iolascon A, Capasso M. Cardinale A, et al. Among authors: testori a. Hum Mol Genet. 2022 Mar 21;31(6):863-874. doi: 10.1093/hmg/ddab293. Hum Mol Genet. 2022. PMID: 34605909 Free PMC article.
Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene.
Avitabile M, Succoio M, Testori A, Cardinale A, Vaksman Z, Lasorsa VA, Cantalupo S, Esposito M, Cimmino F, Montella A, Formicola D, Koster J, Andreotti V, Ghiorzo P, Romano MF, Staibano S, Scalvenzi M, Ayala F, Hakonarson H, Corrias MV, Devoto M, Law MH, Iles MM, Brown K, Diskin S, Zambrano N, Iolascon A, Capasso M. Avitabile M, et al. Among authors: testori a. Carcinogenesis. 2020 May 14;41(3):284-295. doi: 10.1093/carcin/bgz153. Carcinogenesis. 2020. PMID: 31605138 Free PMC article.
Germline Polymorphisms of the VEGF Pathway Predict Recurrence in Nonadvanced Differentiated Thyroid Cancer.
Marotta V, Sciammarella C, Capasso M, Testori A, Pivonello C, Chiofalo MG, Gambardella C, Grasso M, Antonino A, Annunziata A, Macchia PE, Pivonello R, Santini L, Botti G, Losito S, Pezzullo L, Colao A, Faggiano A. Marotta V, et al. Among authors: testori a. J Clin Endocrinol Metab. 2017 Feb 1;102(2):661-671. doi: 10.1210/jc.2016-2555. J Clin Endocrinol Metab. 2017. PMID: 27849428
Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib.
Marotta V, Sciammarella C, Capasso M, Testori A, Pivonello C, Chiofalo MG, Pivonello R, Pezzullo L, Botti G, Colao A, Faggiano A. Marotta V, et al. Among authors: testori a. Endocrine. 2017 Sep;57(3):539-543. doi: 10.1007/s12020-016-1200-6. Epub 2016 Dec 16. Endocrine. 2017. PMID: 27981515 No abstract available.
Erratum to: Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib.
Marotta V, Sciammarella C, Capasso M, Testori A, Pivonello C, Chiofalo MG, Pivonello R, Pezzullo L, Botti G, Colao A, Faggiano A. Marotta V, et al. Among authors: testori a. Endocrine. 2017 Sep;57(3):544. doi: 10.1007/s12020-017-1269-6. Endocrine. 2017. PMID: 28243971 No abstract available.
Molecular Diagnostic Outcomes from 700 Cases: What Can We Learn from a Retrospective Analysis of Clinical Exome Sequencing?
Murrell JR, Nesbitt AMI, Baker SW, Pechter KB, Balciuniene J, Zhao X, Denenberg EH, DeChene ET, Wu C, Jayaraman P, Cao K, Gonzalez M, Devoto M, Testori A, Monos JD, Dulik MC, Conlin LK, Luo M, McDonald Gibson K, Guan Q, Sarmady M, Bhoj E, Helbig I, Zackai EH, Bedoukian EC, Wilkens A, Tarpinian J, Izumi K, Skraban CM, Deardorff MA, Medne L, Krantz ID, Krock BL, Santani AB. Murrell JR, et al. Among authors: testori a. J Mol Diagn. 2022 Mar;24(3):274-286. doi: 10.1016/j.jmoldx.2021.12.002. Epub 2022 Jan 19. J Mol Diagn. 2022. PMID: 35065284 Free PMC article.
In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.
Bossi D, Cicalese A, Dellino GI, Luzi L, Riva L, D'Alesio C, Diaferia GR, Carugo A, Cavallaro E, Piccioni R, Barberis M, Mazzarol G, Testori A, Punzi S, Pallavicini I, Tosti G, Giacó L, Melloni G, Heffernan TP, Natoli G, Draetta GF, Minucci S, Pelicci P, Lanfrancone L. Bossi D, et al. Among authors: testori a. Cancer Discov. 2016 Jun;6(6):650-63. doi: 10.1158/2159-8290.CD-15-1200. Epub 2016 May 13. Cancer Discov. 2016. PMID: 27179036
349 results